Drug Trial Radar · NCT04178967
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: May 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
445
Actual
Start
Oct 29, 2019
Primary completion
Jul 12, 2021
Study completion Apr 28, 2022
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Dermira, Inc.
- First posted
- Nov 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.
Conditions
- Atopic Dermatitis
Interventions
LebrikizumabBiological
Subcutaneous injection
PlaceboOther
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16Time frame: Baseline to Week 16
- Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16Time frame: Baseline to Week 16
Locations
89 sites in 8 countries. Site status is shown where the registry gives one.
Investigate MD
Scottsdale, Arizona
Northwest Arkansas Clinical Trials Center
Rogers, Arkansas
Bakersfield Dermatology and Skin Cancer Medical Group
Bakersfield, California
Center For Dermatology Clinical Research, Inc.
Fremont, California
Woodward Centre
Fresno, California
Dermatology Research Associates
Los Angeles, California
LA Universal Research Center, INC
Los Angeles, California
University Clinical Trials, Inc.
San Diego, California
San Luis Dermatology & Laser Clinic
San Luis Obispo, California
Clinical Physiology Associates, Clinical Study Center
Fort Myers, Florida
Direct Helpers Medical Center
Hialeah, Florida
The Community Research of South Florida
Hialeah, Florida
Solutions Through Advanced Research, Inc.
Jacksonville, Florida
Georgia Pollens Clinical Research Centers, Inc
Albany, Georgia
Marietta Dermatology Clinical Research
Marietta, Georgia
Advanced Medical Research
Sandy Springs, Georgia
Arlington Dermatology
Rolling Meadows, Illinois
NorthShore University HealthSystem
Skokie, Illinois
Kansas City Dermatology, PA
Overland Park, Kansas
Meridian Clinical Research
Baton Rouge, Louisiana
ActivMed Practices and Research
Beverly, Massachusetts
Tufts Medical Center
Boston, Massachusetts
Great Lakes Research Group, Inc.
Bay City, Michigan
Clarkston Skin Research
Clarkston, Michigan
Associated Skin Care Specialists
Fridley, Minnesota
Central Dermatology PC
St Louis, Missouri
Forest Hills Dermatology Group
Kew Gardens, New York
OnSite Clinical Solutions
Charlotte, North Carolina
Wilmington Dermatology Center
Wilmington, North Carolina
Dermatology and Skin Surgery Center
Exton, Pennsylvania
DermDOX
Hazleton, Pennsylvania
Peak Research LLC
Upper Saint Clair, Pennsylvania
Dermatology & Laser Center of Charleston
Charleston, South Carolina
Palmetto Clinical Trial Services
Greenville, South Carolina
Arlington Research Center, Inc
Arlington, Texas
Innovate Research, LLC
Fort Worth, Texas
Austin Institute for Clinical Research
Pflugerville, Texas
University of Utah MidValley Dematology
Murray, Utah
Virginia Clinical Research, Inc.
Norfolk, Virginia
Dermatology Associates
Seattle, Washington
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.